Encore Therapeutics Inc. Announces Successful Proof of Concept Study on Meloxicam Depot Injection
10/18/2011 11:15:26 AM
CARLSBAD, Calif.--(BUSINESS WIRE)--Encore Therapeutics Inc. (ETI) today announced that it successfully completed a pre-clinical Proof of Concept (POC) study on ETI-511, its proprietary, extended release phospholipid gel (PG) depot formulation of the NSAID drug meloxicam (Mobec™). The company is developing ETI-511 as a long-acting local therapy for pain and inflammation. The key findings from the POC study are: (a) ETI-511 provided about 100-fold higher local tissue levels of meloxicam for at least 48 hours around the injection site compared to orally dosed meloxicam. (b) ETI-511 exhibited lower plasma meloxicam levels at all times compared to the oral dosing and (c) ETI-511 was well tolerated locally and systemically following subcutaneous injections.
comments powered by